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Although several vaccine candidates are presently in various phases of clinical trials, the ﬁeld still lacks an
effective tool to determine protective immunity. The presence of cross-neutralizing antibodies limits a
serological approach to identify the etiology and distinguish lifelong from short-lived humoral protec-
tion. A recent study indicated that cross-reactive but not serotype-speciﬁc antibodies require high anti-
body concentration to co-ligate FccRIIB and inhibit infection. Here, we tested if these differences could
allow us to distinguish serotype-speciﬁc from cross-neutralizing antibodies. Using 30 blinded early con-
valescent serum samples from patients with virologically conﬁrmed dengue, we demonstrate that neu-
tralization in the presence of FccR-mediated phagocytosis in THP-1 correctly identiﬁes the DENV
serotype of the infection in 93.3% of the cases compared to 76.7% with plaque reduction neutralization
test. Our ﬁndings could provide a new approach for evaluating DENV neutralization and suggest that
in addition to blocking speciﬁc ligand–receptor interactions for viral entry, antibodies must prevent viral
uncoating during FccR-mediated phagocytosis for complete humoral protection.
 2012 Elsevier B.V. Open access under CC BY-NC-ND license. The re-emergence of dengue throughout the tropical world con-
tinues unabated without sustainable preventative measures. The
presence of four antigenically distinct dengue virus (DENV) sero-
types has complicatedvaccinedevelopment. In particular, the possi-
bility of enhanced infection by non- or sub-neutralizing levels of
antibodies necessitates that any vaccine must protect against all
four serotypes. Furthermore, there is also a lack of an effective
surrogate marker of protective immunity. The plaque reduction
neutralization test (PRNT) and various adaptations of this test have
been used to measure neutralizing antibody titers and infer immu-
nity (Putnak et al., 2008; Roehrig et al., 2008). However, thepresence
of cross-neutralizing antibodies especially following a secondary
infection with a heterologous DENV serotype or ﬂavivirus vaccina-
tion limits the ability of PRNT to serve as a surrogate marker for
humoral immunity (Endy et al., 2004). Understanding the require-
ments for humoral immunity could thus pave the way for vaccine
and therapeutic antibody development.
We recently demonstrated a mechanistic role for FccRIIB in
inhibiting phagocytosis of antibody-opsonized DENV (Chan et al.,
2011). Using a limited number of convalescent serum samples ob-
tained within 3 weeks from illness onset as well as humanizedate Medical School, Program
69857 Singapore, Singapore.
. Ooi).
-NC-ND license. monoclonal antibody, we observed that neutralization of homolo-
gous DENV serotypes occurred at serum dilutions that permitted
FccR-mediated phagocytosis but neutralization of heterologous
DENV serotypes only occurred at serum dilutions that aggregates
DENV to co-ligate FccRIIB, resulting in downstream signaling that
inhibits phagocytosis (Chan et al., 2011). This ﬁnding suggests that
serotype-speciﬁc neutralization can be differentiated from cross-
reactive antibodies by assessing for neutralization in the presence
of FccR-mediated phagocytosis. This is important as long-lasting
humoral immunity following DENV infection is directed at the
homologous but not heterologous serotypes (Sabin, 1952). Here,
we report a clinical validation of detecting DENV neutralization
in the presence of FccR-mediated phagocytosis.
We took advantage of the known presence of cross-neutralizing
antibodies in early convalescence following a primary DENV infec-
tion (Beltramello et al., 2010; Dejnirattisai et al., 2010), which
would enable us to compare a serological determination of the
serotype of infection with the virological ﬁndings in the acute sera
and determine its accuracy, unequivocally, for this study. We de-
signed an investigator-blinded test of early convalescent serum
samples obtained from patients with virologically conﬁrmed DENV
infection. A schematic illustration of the study approach is shown
in Fig. 1. Human sera used in this study were obtained from the
early dengue infection and control (EDEN) study as previously de-
scribed (Low et al., 2006) and approved by the National Healthcare
Group Domain Speciﬁc Review Board (DSRB B/05/013). These
Fig. 1. Workﬂow of the study. PRNT50 and 100% DENV neutralization in THP-1 were determined for all 30 early convalescent samples. The highest neutralization titer from
PRNT50/100% neutralization in THP-1 was taken to indicate the serotype of infection as conventionally used by other studies. Furthermore, based on 100% neutralization in
THP-1, confocal immunoﬂuorescence was performed to determine the presence or absence of co-localization of labeled antibody-virus complexes. Presence of co-localization
of antibody-virus complexes with LAMP-1 was taken to indicate the presence of serotype-speciﬁc antibodies (white arrows), while inhibition of FccR-mediated phagocytosis
was taken to signify the presence of only cross-reactive antibodies. Green – LAMP-1, red – human IgG, blue – DiD labeled DENV.
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written informed consent for the use of material and clinical infor-
mation for research purposes. Patients included in this study had
positive RT-PCR ﬁndings but negative anti-dengue IgG in the acute
serum samples (obtained within 72 h from illness onset) as mea-
sured by ELISA (PanBio). The presence of pre-existing anti-ﬂavivi-
rus antibodies such as those against Japanese encephalitis virus,
yellow fever and West Nile virus was not assessed although the
ELISA would have detected cross-reactive antibodies from prior
infection or vaccination with these viruses. A priori statistical cal-
culation using Wilson’s approach for calculating two sided conﬁ-
dence intervals, indicated that a sample size of 30 would provide
a proportion estimate of 0.9 with a pre-set 90% conﬁdence interval
width of less than 0.20 (0.77,0.96) (PASS  2010 Software). Hence,
by convenience sampling, 30 convalescent sera were selected and
coded by one of the co-authors (AC). Subsequent studies were car-
ried out by all other authors blinded to the ﬁndings in the acute
sera. The selected sera were collected at a median of 18 days (min-
imum 12 days, maximum 32 days) from illness onset.
PRNT50 and DENV neutralization in THP-1 were carried out on
the convalescent sera as described previously (Chan et al., 2011).
In these experiments, DENV-1 (07K2402DK1), DENV-2 (ST),
DENV-3 (05K802DK1) and DENV-4 (05K2270DK1) were used. To
determine PRNT50 titers, serial 2-fold dilutions of the sera were
incubated with 40 pfu of DENV at 37 C for 1 h before adding to
BHK-21. The serotype with the highest dilution that neutralized
50% of the plaque forming units was interpreted as causative of
the acute infection. Complete (100%) DENV neutralization in
THP-1 was determined by incubating serial 2-fold dilutions of sera
with DENV, before adding to THP-1 at a multiplicity of infection of
10. After 72 h incubation, plaque assay on BHK-21 was performed
on the THP-1 culture supernatant. The serotype with the highest
dilution that neutralized 100% of DENV was interpreted ascausative of the acute infection. We also reacted sera with DiD
(1,1-dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine, 4-chloro-
benzenesulfonate salt)-labeled DENV (van der Schaar et al.,
2007), at dilutions where 100% neutralization of DENV was seen
in THP-1 and performed confocal immunoﬂuorescence microscopy
to assess for FccR-mediated phagocytosis at 30 min post-inocula-
tion (Fig. 1). Complete DENV neutralization with FccR-mediated
phagocytosis was taken as the serotype of the acute infection
(Fig. 1). The RT-PCR ﬁndings in the respective acute sera were
un-blinded only upon completion of the serological analyses.
Of the 30 convalescent samples, only eight (26.7%) showed
PRNT50 to a single serotype. Similarly, these eight sera displayed
neutralizing titers to a single serotype in THP-1, all of which neu-
tralized DENV in the presence of FccR-mediated phagocytosis (Ta-
ble 1). Among the remaining 22 convalescent sera, the highest
PRNT50 titer was consistent with the serotype detected by RT-
PCR in the acute sera in 15 cases (68.2%, 95% conﬁdence interval
(95% CI) 45.0–86.1%). In the 11 samples where the highest PRNT50
titer was at least 4-fold or higher than those of the other serotypes,
the highest PRNT50 titer was consistent with the serotype of the
infection. However, in the other 11 of the samples that showed
(i) identical titers to two serotypes or (ii) only 2-fold difference be-
tween the highest and the next highest titer, only 4 (36%) were
consistent with the serotype of the infection (Table 1).
Using the highest dilution that mediated 100% DENV neutraliza-
tion in THP-1, only 13 out of the 22 cases correctly identiﬁed the
serotype of infection (59.1%, 95% CI 36.4–79.3%) (Table 1). Confocal
imaging, however, clariﬁed the serotype of the acute infection,
where 20 out of the 22 cases (90.9%, 95% CI 70.8–98.9%) showed
complete DENV neutralization in the presence of FccR-mediated
phagocytosis (Table 1). Overall, the accuracy of PRNT50, 100%
neutralization in THP-1 and confocal imaging were 76.7% (95% CI
57.7–90.1%), 70.0% (95% CI 50.6–85.3%) and 93.3% (95% CI
Table 1
Correlation of PRNT50, 100% dengue neutralization in THP-1 and FccR-mediated phagocytosis with serotype of infection as determined by RT-PCR for DENV in the corresponding
acute serum samples.
No. of early convalescent sera No. of sera correlated with serotype of infection
PRNT50 100% neutralization in THP-1 FccR-mediated phagocytosis
Homotypic 8 8 8 8
Heterotypic 22 15 13 20
Total 30 23 21 28
Fig. 2. Accuracy of PRNT50 and 100% neutralization in THP-1 with or without observing for Fc-receptor-mediated phagocytosis in identifying the serotype of the acute
infection. Number of patient samples predicted correctly for (A) DENV-1 (n = 10), (B) DENV-2 (n = 6) and (C) DENV-3 (n = 14) using either PRNT50, 100% neutralization in THP-
1 or observing for FccR-mediated phagocytosis. Patient samples with only one neutralization titer are classiﬁed as homotypic (Grey bars) and samples with more than one
neutralization titers are classiﬁed as heterotypic (White bars). In brackets are percentages in which the serotype determined serologically correlated with the DENV serotype
detected by RT-PCR in the respective acute serum samples.
342 R.S.L. Wu et al. / Antiviral Research 96 (2012) 340–34377.9–99.2%), respectively. Fig. 2 summarizes the results from the
three different methods used in our study by DENV serotype. None
of our patients were infected with DENV-4.
PRNT and most other neutralization assays have used epithelial
cells, such as Vero or BHK-21 as host cells for DENV infection.
These cells neither express FccR nor are they the primary targets
of DENV in vivo. Monocytes, on the other hand, play a central role
in dengue virus replication (Durbin et al., 2008; Halstead, 1988) as
well as the clearance of immune complexes. Using THP-1, which
was derived from a patient with acute monocytic leukemia, we
had observed that convalescent serum could only neutralize the
homologous serotypes in the presence of FccR-mediated phagocy-
tosis (Chan et al., 2011). Our present ﬁnding supports this hypoth-
esis and demonstrates that such an approach could be used to
determine the serotype of the infection. This approach could be
useful in assessing the efﬁcacy of vaccination to each of the four
DENV serotypes. As the tetravalent formulation of candidate den-
gue vaccines would elicit pan-dengue antibodies, clarifying
whether these antibodies are able to neutralize each of the four
DENV serotypes in the presence of FccR phagocytosis, similar to
antibodies generated following an acute infection, could inform
on whether vaccination is likely to result in long-term serotype-
speciﬁc immunity.
Our current ﬁndings also raise important questions. It is not evi-
dent why neutralization of heterologous serotypes could not occur
in the presence of FccR-mediated phagocytosis. It is possible that
cross-reactive antibodies need higher amounts of antibodies to ful-
ﬁll the stoichiometric requirement for DENV neutralization com-
pared to serotype-speciﬁc antibodies (Pierson et al., 2007) and
these antibody concentrations coincide with that which aggregates
DENV for FccRIIB co-ligation (Chan et al., 2011). It is also possible
that the cross-reactive antibodies to DENV antigens have lowerbinding afﬁnities that are compromised in the low pH environment
within phagosomes. Indeed, serotype-speciﬁc antibodies appear to
be more potent in DENV neutralization although cross-reactive
antibodies were more abundant in convalescent sera (de Alwis
et al., 2012). Hence, we suggest that in addition to blocking speciﬁc
ligand-receptor interactions for viral entry, antibodies must pre-
vent viral uncoating during FccR-mediated phagocytosis for
complete humoral protection. Clarifying this could be important
for identifying suitable antibodies for therapeutic development
(de Alwis et al., 2011, 2012; Teoh et al., 2012).
In conclusion, determining if virus neutralization occurs in the
presence of FccR-mediated phagocytosis can clarify the serotype
of the DENV infection serologically.Acknowledgements
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